A novel GSH responsive poly(alpha-lipoic acid) nanocarrier bonding with the honokiol-DMXAA conjugate for combination therapy
Source abstract
Abstract
The key to improve the therapeutic efficacy for cancer treatment is to increase the delivery of drugs to tumors. For this purpose, tumor-microenvironment stimuli- responsive materials have great potential. Here, we prepared a new nanomedicine by bonding the conjugate of honokiol (HNK) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) to a glutathione (GSH)-responsive nanocarrier, poly( α -lipoic acid) polyethylene glycol. The nanomedicine would disintegrate due to the high level of GSH at the tumor sites, achieving the co-delivery of HNK and DMXAA, and realizing the combination therapy through close-range killing by HNK and long-range striking by DMXAA together. In a murine 4T1 breast tumor model, this strategy exhibited high tumor inhibition rate of 93%, and provided a valuable therapeutic choice for cancer therapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Biochemical Acid Research Studies · Macrophage Migration Inhibitory Factor · Histone Deacetylase Inhibitors Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Chen H, Gu Z, An H, et al. Precise nanomedicine for intelligent therapy of cancer. Sci China Chem, 2018, 61: 1503–155210.1007/s11426-018-9397-5 ↗
2. Chen J, Lin L, Yan N, et al. Macrophages loaded CpG and GNR-PEI for combination of tumor photothermal therapy and immunotherapy. Sci China Mater, 2018, 61: 1484–149410.1007/s40843-018-9238-6 ↗
3. Hasani A, Leighl N. Classification and toxicities of vascular disrupting agents. Clin Lung Cancer, 2011, 12: 18–2510.3816/CLC.2011.n.002 ↗
4. Daei Farshchi Adli A, Jahanban-Esfahlan R, Seidi K, et al. An overview on vadimezan (DMXAA): the vascular disrupting agent. Chem Biol Drug Des, 2018, 91: 996–100610.1111/cbdd.13166 ↗
5. Bähr O, Gross S, Harter P, et al. ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors. Oncol Lett, 2017, 14: 5443–5451
6. Hohenberger P, Elleni S, Marc F, et al. Vascular disrupting agent ASA 404 evaluated in human isolated ventilated and perfused lung lobes containing NSCLC. Eur J Cancer, 2015, 51: S60810.1016/S0959-8049(16)31678-1 ↗
7. Lv S, Tang Z, Song W, et al. Inhibiting solid tumor growth in vivo by non-tumor-penetrating nanomedicine. Small, 2017, 13: 160095410.1002/smll.201600954 ↗
8. Song W, Tang Z, Zhang D, et al. Solid tumor therapy using a cannon and pawn combination strategy. Theranostics, 2016, 6: 1023–103010.7150/thno.14741 ↗
9. Cheng R, Meng F, Deng C, et al. Bioresponsive polymeric nanotherapeutics for targeted cancer chemotherapy. Nano Today, 2015, 10: 656–67010.1016/j.nantod.2015.09.005 ↗
10. Cheng R, Meng F, Deng C, et al. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials, 2013, 34: 3647–365710.1016/j.biomaterials.2013.01.084 ↗
11. Ganta S, Devalapally H, Shahiwala A, et al. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release, 2008, 126: 187–20410.1016/j.jconrel.2007.12.017 ↗
12. Thornton P, Mart R, Ulijn R. Enzyme-responsive polymer hydrogel particles for controlled release. Adv Mater, 2007, 19: 1252–125610.1002/adma.200601784 ↗
13. Chen K, Liao S, Guo S, et al. Enzyme/pH-sensitive dendritic polymer-DOX conjugate for cancer treatment. Sci China Mater, 2018, 61: 1462–147410.1007/s40843-018-9277-8 ↗
14. Du JZ, Du XJ, Mao CQ, et al. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J Am Chem Soc, 2011, 133: 17560–1756310.1021/ja207150n ↗
15. Du JZ, Sun TM, Song WJ, et al. A tumor-acidity-activated charge-conversional nanogel as an intelligent vehicle for promoted tumoral-cell uptake and drug delivery. Angew Chem Int Ed, 2010, 49: 3621–362610.1002/anie.200907210 ↗
16. Xu Q, He C, Xiao C, et al. Reactive oxygen species (ROS) responsive polymers for biomedical applications. Macromol Biosci, 2016, 16: 635–64610.1002/mabi.201500440 ↗
17. Yuan F, Li JL, Cheng H, et al. A redox-responsive mesoporous silica based nanoplatform for in vitro tumor-specific fluorescence imaging and enhanced photodynamic therapy. Biomater Sci, 2017, 6: 96–10010.1039/C7BM00793K ↗
18. Chen D, Zhang G, Li R, et al. Biodegradable, hydrogen peroxide, and glutathione dual responsive nanoparticles for potential programmable paclitaxel release. J Am Chem Soc, 2018, 140: 7373–737610.1021/jacs.7b12025 ↗
19. Elzes MR, Akeroyd N, Engbersen JFJ, et al. Disulfide-functional poly(amido amine)s with tunable degradability for gene delivery. J Control Release, 2016, 244: 357–36510.1016/j.jconrel.2016.08.021 ↗
20. Zhang P, Wu J, Xiao F, et al. Disulfide bond based polymeric drug carriers for cancer chemotherapy and relevant redox environments in mammals. Med Res Rev, 2018, 38: 1485–151010.1002/med.21485 ↗
21. Perry RR, Mazetta J, Levin M, et al. Glutathione levels and variability in breast tumors and normal tissue. Cancer, 1993, 72: 783–78710.1002/1097-0142(19930801)72:3<783::AID-CNCR2820720325>3.0.CO;2-U ↗
22. Huang ZZ, Chen C, Zeng Z, et al. Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration. Faseb J, 2001, 15: 19–2110.1096/fj.00-0445fje ↗
23. Wolf CR, Lewis AD, Carmichael J, et al. The role of glutathione in determining the response of normal and tumour cells to anticancer drugs. Biochm Soc Trans, 1987, 15: 728–73010.1042/bst0150728 ↗
24. Schnelldorfer T, Gansauge S, Gansauge F, et al. Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer, 2000, 89: 1440–144710.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.0.CO;2-0 ↗
25. Lee MH, Yang Z, Lim CW, et al. Disulfide-cleavage-triggered chemosensors and their biological applications. Chem Rev, 2013, 113: 5071–510910.1021/cr300358b ↗
26. Nie JJ, Qiao B, Duan S, et al. Unlockable nanocomplexes with self-accelerating nucleic acid release for effective staged gene therapy of cardiovascular diseases. Adv Mater, 2018, 30: 180157010.1002/adma.201801570 ↗
27. Liu Z, Shen N, Tang Z, et al. An eximious and affordable GSH stimulus-responsive poly(α-lipoic acid) nanocarrier bonding combretastatin A4 for tumor therapy. Biomater Sci, 2019, 7: 2803–281110.1039/C9BM00002J ↗
28. Kisanuki A, Kimpara Y, Oikado Y, et al. Ring-opening polymerization of lipoic acid and characterization of the polymer. J Polym Sci A Polym Chem, 2010, 48: 5247–525310.1002/pola.24325 ↗
29. Ishida H, Kisanuki A, Endo K. Ring-opening polymerization of aromatic 6-membered cyclic disulfide and characterization of the polymer. Polym J, 2009, 41: 110–11710.1295/polymj.PJ2008219 ↗